Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis

ABSTRACT Efavirenz (EFZ) has been associated with neuropsychiatric side effects. Recently, the 8-hydroxy-EFZ (8OH-EFZ) metabolite has been shown to be a potent neurotoxin in vitro, inducing neuronal damage at concentrations of 3.3 ng/ml. EFZ induced similar neuronal damage at concentrations of 31.6 ng/ml. We investigated the effect of genotype and blood-brain barrier integrity on EFZ metabolite concentrations in cerebrospinal fluid (CSF). We measured CSF drug concentrations in subjects from two separate study populations: 47 subjects with tuberculous meningitis (TBM) coinfection in Vietnam receiving 800 mg EFZ with standard antituberculous treatment and 25 subjects from the PARTITION study in the United Kingdom without central nervous system infection receiving 600 mg EFZ. EFZ and metabolite concentrations in CSF and plasma were measured and compared with estimates of effectiveness and neurotoxicity from available published in vitro and in vivo data. The effect of the CYP2B6 c.516G→T genotype (GG genotype, fast EFV metabolizer status; GT genotype, intermediate EFV metabolizer status; TT genotype, slow EFV metabolizer status) was examined. The mean CSF concentrations of EFZ and 8OH-EFZ in the TBM group were 60.3 and 39.3 ng/ml, respectively, and those in the no-TBM group were 15.0 and 5.9 ng/ml, respectively. Plasma EFZ and 8OH-EFZ concentrations were similar between the two groups. CSF EFZ concentrations were above the in vitro toxic concentration in 76% of samples (GG genotype, 61%; GT genotype, 90%; TT genotype, 100%) in the TBM group and 13% of samples (GG genotype, 0%; GT genotype, 18%; TT genotype, 50%) in the no-TBM group. CSF 8OH-EFZ concentrations were above the in vitro toxic concentration in 98% of the TBM group and 87% of the no-TBM group; levels were independent of genotype but correlated with the CSF/plasma albumin ratio. Potentially neurotoxic concentrations of 8OH-EFZ are frequently observed in CSF independently of the CYP2B6 genotype, particularly in those with impaired blood-brain barrier integrity.

[1]  C. Leen,et al.  Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia , 2016, Journal of NeuroVirology.

[2]  A. Telenti,et al.  In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid , 2016, Drug Metabolism and Disposition.

[3]  H. Jessen,et al.  Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Antunes,et al.  The phenolic metabolites of the anti-HIV drug efavirenz: evidence for distinct reactivities upon oxidation with Frémy's salt. , 2014, European journal of medicinal chemistry.

[5]  J. McArthur,et al.  Dendritic Spine Injury Induced by the 8-Hydroxy Metabolite of Efavirenz , 2012, Journal of Pharmacology and Experimental Therapeutics.

[6]  Namandjé N. Bumpus.  Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. , 2011, Toxicology and applied pharmacology.

[7]  C. Hendrix,et al.  The Male Genital Tract Is Not a Pharmacological Sanctuary From Efavirenz , 2011, Clinical pharmacology and therapeutics.

[8]  J. Farrar,et al.  Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Kwang-Hyeon Liu,et al.  Rapid and Simultaneous Determination of Efavirenz, 8-Hydroxyefavirenz, and 8,14-Dihydroxyefavirenz Using LC–MS–MS in Human Plasma and Application to Pharmacokinetics in Healthy Volunteers , 2011 .

[10]  A. Amara.  Development and validation of a HPLC-MS/MS assay to quantify the anti-retroviral (ARV) drug, efavirenz and its major metabolites in plasma , 2011 .

[11]  Y. Teo,et al.  Genomic copy number variations in three Southeast Asian populations , 2010, Human mutation.

[12]  L. Milani,et al.  A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. , 2009, British journal of clinical pharmacology.

[13]  M. J. García,et al.  Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients , 2009, Antimicrobial Agents and Chemotherapy.

[14]  A. Telenti,et al.  Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals , 2009, Clinical pharmacology and therapeutics.

[15]  Huldrych F. Günthard,et al.  In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function , 2009, Pharmacogenetics and genomics.

[16]  Shuji Ohno,et al.  Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction , 2009, Drug Metabolism and Disposition.

[17]  J. Farrar,et al.  Clinical and Microbiological Features of HIV-Associated Tuberculous Meningitis in Vietnamese Adults , 2008, PloS one.

[18]  M Schwab,et al.  Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals , 2007, Clinical pharmacology and therapeutics.

[19]  A. Telenti,et al.  Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents , 2006, Current HIV/AIDS reports.

[20]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[21]  S. Khoo,et al.  Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. , 2005, The Journal of antimicrobial chemotherapy.

[22]  A. Tunkel.  Dexamethasone for treatment of tuberculous meningitis in adolescents and adults , 2005, Current infectious disease reports.

[23]  Amalio Telenti,et al.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.

[24]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[25]  S. Oka,et al.  Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. , 2004, Biochemical and Biophysical Research Communications - BBRC.

[26]  A. Sönnerborg,et al.  Efavirenz Plasma Concentrations in HIV-Infected Patients: Inter- and Intraindividual Variability and Clinical Effects , 2004, Therapeutic drug monitoring.

[27]  R. Tyndale,et al.  The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics , 2004, Drug metabolism reviews.

[28]  D. Mash,et al.  Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.

[29]  David A. Flockhart,et al.  The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[30]  Jacques Fellay,et al.  Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection , 2003, Clinical pharmacology and therapeutics.

[31]  J. Barrett,et al.  Population pharmacokinetic meta-analysis with efavirenz. , 2002, International journal of clinical pharmacology and therapeutics.

[32]  A. Telenti,et al.  Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .

[33]  M. Boyd,et al.  Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. , 2000, Biochemical pharmacology.

[34]  T. Tephly,et al.  Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. , 1999, Archives of biochemistry and biophysics.

[35]  K. Blennow,et al.  Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. , 1993, European neurology.

[36]  R. Bulger,et al.  Antimicrobial Agents and Chemotherapy , 1969, Nature.